It is noteworthy that since March 2020 tocilizumab has been formally included in the National Health Commission of China's COVID‐19 diagnosis and treatment program (7th edition): ‘Tocilizumab can be used in patients with extensive bilateral lung lesion opacity or in severe or critical patients, who have elevated IL‐6 levels’. Here, IL6 is linked to COVID-19.